Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase NA 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Prostatic Neoplasms 76Urinary Bladder Neoplasms 20Neoplasms 11Carcinoma, Transitional Cell 8Non-Muscle Invasive Bladder Neoplasms 6Lung Neoplasms 6Carcinoma, Renal Cell 6Neoplasm Metastasis 5Breast Neoplasms 4Testicular Neoplasms 3Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Kidney Neoplasms 3Colorectal Neoplasms 3Carcinoma in Situ 3Adenocarcinoma 3Acute Kidney Injury 3Uterine Cervical Neoplasms 2Prostate CA 2Melanoma 2Liver Neoplasms 2Kidney Failure, Chronic 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Gallbladder Neoplasms 2Critical Illness 2Colonic Neoplasms 2Agnosia 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasm Recurrence, Local × Genitourinary × Clear all
NCT00406068 2016-07-28

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Bioniche Life Sciences Inc.

Phase 2/3 Completed
129 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local

Data powered by HemOnc (CC BY 4.0) Colophon âš¡